TrumpRx’s promised drug-price cuts expose a deeper systemic flaw, positioning direct-to-patient clinical pathways as the infrastructure pharma must build to turn political headlines into real access and outcomes.
Pouria Sanae
Advertisement
Co-founder and CEO, ixlayer
Articles by Pouria Sanae
Physicians remain central even as DTP programs are implemented.
Advertisement
Latest Updated Articles
Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be ApplaudedPublished: January 16th 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
5
